PURPOSE. Superselective intraophthalmic artery chemotherapy (SSIOAC) is being used for treatment of retinoblastoma; however, the hemodynamic consequences and toxicities are not fully known. We developed a nonhuman primate (NHP) model of SSIOAC and reported our clinical observations. For validation, we compared ophthalmic artery (OA) diameters between NHPs and children (<6 years).
RESULTS.
The median angiographic diameter of treated NHP OA origins (n ¼ 6) was 1.06 mm (range 0.94-1.56). Histologic measurements (8 of 12 NHP OAs) gave a median diameter of 1.09 mm (range 0.95-1.41). In 98 children (from 169 consecutive CT and MR angiography studies; median age 1.01 years, range 0.01-5.74), 186 OAs were measurable at the origin (median luminal diameter 1.28 mm, range 0.82-2.00; P ¼ 0.16 for the angiographic NHP diameters versus pediatric cohort). Angiographic measurements of 34 OAs (of 20 consecutive studies of adolescents; median age 16.55 years, range 14.40-18.18) gave a median luminal diameter of 1.45 mm (origin, range 1.13-1.66; P < 0.0001, adolescent versus pediatric).
CONCLUSIONS. Measurements of the OA luminal diameter at its origin were similar between our NHP and pediatric cohort, validating our NHP model for testing both the hemodynamic consequences and toxicities of SSIOAC. (Invest Ophthalmol Vis Sci. 2012;53:7791-7794) DOI:10.1167/iovs.12-10605 P rimarily, the treatment of retinoblastoma aims to save lives; secondarily, to save the eye and preserve vision. Retinoblastoma treatment has evolved over the past several decades: from external beam radiation to intravenous systemic chemotherapy to localized chemotherapy through arterial cannulation of the internal carotid system. Therapies have shifted to place more emphasis on globe salvage. Superselective intraophthalmic artery chemotherapy (SSIOAC) is currently being used for the treatment of retinoblastoma. SSIOAC, a technique modeled from the early work of Kaneko, 1 delivers a high dose of intraocular concentrations of chemotherapeutic agents by direct cannulation of the ophthalmic artery (OA), thus reducing unwanted systemic toxicities. Since 2008, SSIOAC has been used at select institutions for treatment of advanced retinoblastoma, 2 and it has been increasingly offered for the treatment of certain primary or secondary tumors. [3] [4] [5] [6] [7] [8] [9] [10] [11] While SSIOAC has proven to demonstrate remarkable tumor regression, an increasing number of institutions are reporting cases of retinal toxicity, vascular damage, and ocular morbidity. [5] [6] [7] [8] [12] [13] [14] [15] [16] [17] [18] SSIOAC may offer a theoretical advantage in the treatment of retinoblastoma, yet further investigation is needed to master the technical aspects of the procedure, to understand the hemodynamic consequences of endovascular cannulation, and to define drug toxicities.
To study and better understand SSIOAC, we developed a nonhuman primate (NHP) model to observe, with real-time imaging, the consequences of SSIOAC. 19, 20 To validate our model, we compared OA diameters between our NHPs and a cohort of children less than 6 years of age.
METHODS

Nonhuman Primate Model
Approval was received from the institution's animal care and use committee. All animals were treated in accordance with ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Endovascular cannulation of the right OA was performed three times each in six adult male Rhesus macaques (Macaca mulatta, median age 10.5 years, median weight 11.6 kg, median eye measurements 19 3 19 3 19 mm) for 18 total procedures. Lateral projection angiographic images were obtained prior to each of the three infusions for all animals. Measurements of the NHP OA diameter were made from these images at the first location after the origin, whereby the vessel could be clearly seen in profile without obscuration by mixing of contrast and unopacified blood, typically within 2 to 4 mm of the origin (Fig. A) .
Postmortem dissection of the monkeys was performed after the third SSIOAC treatment. Using a 15-blade scalpel, the scalp of the monkey was reflected to expose the skull. The calvarium was then removed using a bone saw. The brain was removed, taking care to preserve the Circle of Willis and optic nerves. Dura was stripped from the skull base using rongeurs. Rongeurs were then used to remove the roofs of the orbit and optic canal. The levator and superior rectus muscles were reflected using Westcott scissors. Orbital fat was dissected off the vasculature using Jeweler's forceps. The OA and its branches were identified. The optic nerves were carefully removed and preserved in formalin to reveal the origin of the OA. The orbital arterial tree was removed en bloc from the right and the left orbits of each monkey and placed into 10% neutral buffered formalin. Sections over the entire length of the ophthalmic, central retinal, and lacrimal arteries were placed in paraffin blocks and then serially sectioned for staining with hematoxylin and eosin. Every fifth section was stained and examined. Ten measurements of the luminal diameter were taken along the entire length of each OA to yield an average diameter (Olympus DP Controller [DP-BSW], ver. 3.3.1.292, Olympus Corporation, Center Valley, PA). Average diameters were obtained for eight of the 12 eyes dissected, with tissue sections from the other four eyes unavailable due to processing difficulties.
Noninvasive Analysis of Human Pediatric Ophthalmic Artery
For comparison, we performed an Institutional Review Board-approved retrospective analysis of computed tomography (CT) and magnetic resonance (MR) angiography of the head in children less than 6 years of age. A Healthcare Information Portability and Accountability Actcompliant database was searched to identify appropriate studies for review between 2006 and 2011. Using the same database, we also identified 20 consecutive adolescents with measurable vasculature to use as adult references. The studies were consecutive studies. Excluded CT and MR studies included MR venograms, nonvisualization of the OA, excessive motion artifact, high-flow intracranial vascular malformation, carotid artery pathology such as dissection or moyamoya, and duplicate studies on a single patient. Additionally, patients with retinoblastoma or other orbital tumors, infections, and vascular abnormalities were excluded from the study.
Measurements of the OA luminal diameter on CT and MR studies were made in a plane perpendicular to the long-axis of the artery shortly after the origin at the first location where there was no longer rapid tapering of the vessel, usually within 2 mm of the origin (Fig. B) . This was confirmed on sagittal, coronal, and oblique multiplanar reconstructions of the volumetric datasets including use of maximalintensity projections to allow measurement of the true diameter without overestimation of size due to vessel tortuosity and without underestimation of size due to volume-averaging (Figs. C, D) .
Statistics
Data was collected in a spreadsheet application (Microsoft Excel; Microsoft, Inc., Redmond, WA). Statistical calculations were made using a spreadsheet application (Microsoft Excel [Microsoft, Inc.] and SPSS [IBM Corp., Armonk, NY]). A two-tailed Student's t-test was used to compare the size of the origin of the OA in the NHPs and the pediatric patients. Serial measurements were analyzed using repeatedmeasures ANOVA. Also, comparisons were made between the pediatric and adolescent populations at the measurable anatomical locations of the OA in its course to supply the orbit.
RESULTS
In the NHPs, the median angiographic diameter of the OA origin of the six treated right OAs was 1.06 mm (range 0.94 to À1.56; mean 1.18 6 0.26 mm). There were no significant changes between the first, second, or third measurement in any of the macaques (P ¼ NS). We successfully measured 8 of 12 OAs on histology sections obtaining a median diameter of 1.09 mm (range 0.95-1.41, mean 1.15 6 0.24 mm). There was no significant difference between the angiographically and histologically measured OA diameters (P ¼ 0.78). We identified 169 consecutive CT and MR angiography studies of the head in children less than 6 years of age. In 98 of these pediatric patients (48 females, median age 1.01 years [range 0.01-5.74; mean 1.36 6 1.40 years]), 186 OAs were measurable at its origin off the internal carotid artery with a median luminal diameter of 1.28 mm (range 0.82-2.00; mean 1.29 6 0.16 mm). There was no significant difference in angiographic OA diameter between our NHP and pediatric cohorts (P ¼ 0.16).
In the adolescent group, median age of the 20 adolescents (11 females) was 16.55 years (range 14.40-18.18; mean 16.36 6 0.99 years), 34 OA origins in 18 patients were measurable, with a median luminal diameter of 1.45 mm (range 1.13-1.66; mean 1.42 6 0.11; P < 0.0001, adolescent versus pediatric). There was no significant difference between right and left in any of the measurements made within each age group (P ¼ NS).
DISCUSSION
In our current study, we sought to validate our NHP model by evaluating the size of the pediatric and adolescent OAs and comparing it to the OA size in the macaques.
SSIOAC for the treatment of retinoblastoma has the potential to improve outcomes with decreased morbidity; however, many questions remain unanswered. Without the benefit of a prospective clinically controlled trial, it is unclear if SSIOAC is a translatable technique. 21 We developed the NHP model to study the real-time consequences of SSIOAC. We chose this primate for several reasons. Previous studies demonstrate the macaque as an acceptable animal model for medical research because of its anatomic and physiologic similarity to the human. Specifically, the Rhesus macaque's cephalic arterial system is almost identical to that of a human being, with no major differences in the origin or branching pattern of the OA. 23 The adult male Rhesus macaque is comparable in weight and size to a 2-year-old human being, the age of a child most likely to undergo SSIOAC. 19, 20 Similarly, their eyes are of comparable sizes. Finally, earlier studies identified the macaque as a valid model to study anticancer drug pharmacokinetics. 22, 24, 25 Previous studies have described the complex embryology, anatomic variants, and angiographic techniques to evaluate orbital vasculature. 26 In our current study, we sought to validate our NHP model by evaluating the size of the pediatric and adolescent OAs and compare it to the NHP. We found OA measurements of our NHPs to be similar to those in our pediatric population. Quantitative comparison of the OA in pediatric versus adolescent patients demonstrated vascular growth occurring over the first two decades of life. The OA approaches an adult size of approximately 1.4 mm 27,28 during adolescence, highlighting the pediatric vasculature as a unique and delicate system. Our findings validate our NHP model as a means of studying the toxicities of SSIOAC for the treatment of retinoblastoma.
In our previously published studies, we documented acute ocular vascular toxicities in our NHP model during SSIOAC. 19, 20 Our findings were similar to those reported in children with retinoblastoma treated with SSIOAC. We believe these toxicities result from a complex interaction between drug concentration, drug delivery, inflammatory mediators, leukostasis, and particulates, with an end result of endothelial cell inflammation and apoptosis. How hemodynamic variables, namely the OA diameter, the diameter of the OA relative to diameter of the microcatheter, and the consequences of intermittent pulsatile perfusion impact these complex interactions requires further investigation. This validation study not only provided additional anatomic detail and precision measurement of the arterial system of the NHP macaque 23, 29, 30 but also served as a relevant noncadaveric study 27, 28 of the pediatric OA focusing on a retinoblastoma-pertinent age group-information that is fairly limited in the literature.
Going forth, our data will provide the background for a computational flow model we will use to elucidate the hemodynamic consequences of cannulation and infusion of the OA.
In conclusion, we must appreciate that the drug toxicities and hemodynamic consequences of SSIOAC are not fully known and may be significantly more than previously realized. With this in mind, retinoblastoma specialists are now approaching this treatment with appropriate caution. 5, 13, 21 Treatment algorithms for intraocular retinoblastoma will remain in constant flux without more data to support an efficacious delivery and dosing regimen that is safe for the child. Efforts to explore these and other questions are ongoing, and a Children's Oncology Group Trial has been proposed. 31 In the interim, we will continue our efforts to study and, hopefully, mitigate the observed toxicities.
